NCT04062032View on ClinicalTrials.gov

Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

September 27, 2016

Primary Completion Date

February 27, 2019

Study Completion Date

February 27, 2019

Conditions
Melanoma (Skin)
Interventions
DRUG

Aspirin 81 mg

ASA 81mg taken daily

DRUG

Aspirin 325mg

ASA 325mg taken daily

Trial Locations (1)

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER

NCT04062032 - Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma | Biotech Hunter | Biotech Hunter